Positron-emission tomography and assessment of cancer therapy.

Positron-emission tomography has become an important tool for evaluating tumors, detecting occult cancer, and staging and restaging tumors. This review includes a slideshow with scans from 10 patients with common cancers.

[1]  A. Wolf,et al.  Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  G. Canellos,et al.  Residual mass in lymphoma may not be residual disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Mathis,et al.  A radiosynthesis of fluorine-18 fluoromisonidazole. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  R L Wahl,et al.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  V. Lowe,et al.  Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. , 1994, Radiology.

[6]  David J. Yang,et al.  Detecting recurrent or residual lung cancer with FDG-PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  G Jakse,et al.  Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. , 1996, The Journal of urology.

[8]  Scott T. Grafton,et al.  PET and [18F]-FDG in oncology: a clinical update. , 1996, Nuclear medicine and biology.

[9]  T. Hickish,et al.  Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M Schwaiger,et al.  Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.

[11]  B. Siegel,et al.  Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. , 1998, Annals of surgery.

[12]  M. Phelps,et al.  Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  P. Valk,et al.  Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. , 1999, Archives of surgery.

[14]  S. Barrington,et al.  Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients , 1999, British Journal of Cancer.

[15]  S. Larson,et al.  [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.

[16]  B Ghaye,et al.  Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. , 1999, The European respiratory journal.

[17]  H. Biersack,et al.  Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. , 1999, Hybridoma.

[18]  K R Maravilla,et al.  Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. , 1999, Radiology.

[19]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[20]  S. Gambhir,et al.  A review of the literature for whole-body FDG PET in the management of patients with melanoma. , 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[21]  L. Friberg,et al.  Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. , 2000, European journal of cancer.

[22]  B C Stack,et al.  Surveillance for recurrent head and neck cancer using positron emission tomography. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P F Sharp,et al.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Nährig,et al.  Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Mortelmans,et al.  The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. , 2000, The Journal of thoracic and cardiovascular surgery.

[27]  R. Buchert,et al.  Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  D. Noh,et al.  Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer , 2001, World Journal of Surgery.

[29]  S S Gambhir,et al.  A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  S. Libutti,et al.  A Prospective Study of 2-[18F] Fluoro-2-Deoxy-D-Glucose/Positron Emission Tomography Scan, 99mTc-Labeled Arcitumomab (CEA-Scan), and Blind Second-Look Laparotomy for Detecting Colon Cancer Recurrence in Patients With Increasing Carcinoembryonic Antigen Levels , 2001, Annals of Surgical Oncology.

[31]  R. D'Agostino,et al.  Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer , 2001, Head & neck.

[32]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Ledermann,et al.  Asymptomatic patient with an increasing concentration of CEA. , 2001, The Lancet. Oncology.

[35]  Elisabeth Kjellén,et al.  FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma , 2002, Head and Neck.

[36]  P. Dupont,et al.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  P. V. van Diest,et al.  Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Leonard,et al.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  Paul J. van Diest,et al.  Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography , 2002 .

[40]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[41]  M. Schwaiger,et al.  Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Gould,et al.  The cost of positron emission tomography in six United States Veterans Affairs hospitals and two academic medical centers. , 2003, AJR. American journal of roentgenology.

[43]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[44]  M. Schwaiger,et al.  Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Thomas Beyer,et al.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  H. Kuwano,et al.  Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma , 2004, The British journal of surgery.

[47]  A. Figer,et al.  Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. , 2004, Radiology.

[48]  P. Clavien,et al.  Does the Novel PET/CT Imaging Modality Impact on the Treatment of Patients With Metastatic Colorectal Cancer of the Liver? , 2004, Annals of surgery.

[49]  G. V. von Schulthess.  Positron emission tomography versus positron emission tomography/computed tomography: from "unclear" to "new-clear" medicine. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[50]  G. V. von Schulthess,et al.  Why most PET of lung and head-and-neck cancer will be PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  Osman Ratib,et al.  Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[52]  Ora Israel,et al.  Cancer Recurrence: Diagnostic Value and Impact on Patient Management , 2004 .

[53]  Ora Israel,et al.  Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer? , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  A. Alavi,et al.  Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[55]  G. Schulthess.  Positron emission tomography versus positron emission tomography/computed tomography: from "unclear" to "new-clear" medicine. , 2004 .

[56]  Imran Zoberi,et al.  Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  J. Buatti,et al.  Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. , 2004, International journal of radiation oncology, biology, physics.

[58]  Thomas F Hany,et al.  Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? , 2004, Radiology.

[59]  L. Weih,et al.  Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer , 2005, Head & neck.

[60]  J. Vose,et al.  Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  B. Cheson,et al.  Role of positron emission tomography in lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.